NCT01718236

Brief Summary

The project aims to introduce into clinical practice for Caesarean section conducted under general anesthesia with the rapid induction myorelaxation with rocuronium and the reversal of neuromuscular blockade by using sugammadex. The aim is to demonstrate at least the same efficiency and confirm the safety of the procedure for both mother and newborn compared with older procedure.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Sep 2012

Typical duration for phase_4

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 24, 2012

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 31, 2012

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2015

Completed
Last Updated

July 26, 2016

Status Verified

July 1, 2016

Enrollment Period

2.3 years

First QC Date

October 24, 2012

Last Update Submit

July 22, 2016

Conditions

Keywords

caesarean sectionrocuroniumsugammadex

Outcome Measures

Primary Outcomes (1)

  • time needed to tracheal intubation

    Quality: Rapid induction to general anesthesia with administration propofol and rocuronium for termination the pregnancy by Caesarean section are at least as good as the combination of propofol and succinylcholine iodide.Recording and evaluated will be the time from the beginning as the first drug in the rapid induction to general anesthesia will be administered until the discovery of the first wave of etCO2 after successful intubation (seconds), evaluation of intubation conditions (resistance to laryngoscopy, position of the vocal cords, response to the intubation attempt (limbs movement or cough) scored 1-3 according to level terms, conditions, entry scores for direct visualization of the vocal cords by Cormack-Lehane (I-IV)

    2 years

Secondary Outcomes (1)

  • total procedure time

    2 years

Other Outcomes (1)

  • complications during anesthesia and during perioperation period

    2 years

Study Arms (2)

Rocuronium + sugammadex

EXPERIMENTAL

Intubation after rocuronium administration and reversal of blockade after administration of sugammadex

Drug: Rocuronium + sugammadex

Succinylcholine + Neostigmine

EXPERIMENTAL

Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration

Drug: Succinylcholine + Neostigmine

Interventions

Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.

Rocuronium + sugammadex

1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.

Succinylcholine + Neostigmine

Eligibility Criteria

Age14 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • caesarian section under general anesthesia in informed patient (after interview with anesthesiologist and obtain the signature for informed consent)

You may not qualify if:

  • patient disagreement
  • indicated and performed neuraxial blockade
  • allergy or intolerance to one or more of study drug or known allergies or reactions to iodine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Faculty Hospital Olomouc

Olomouc, Olomoucký kraj, 775 20, Czechia

Location

Faculty hospital Brno

Brno, South Moravian, 62500, Czechia

Location

Related Links

MeSH Terms

Interventions

RocuroniumSugammadexSuccinylcholineNeostigmine

Intervention Hierarchy (Ancestors)

AndrostanolsAndrostanesSteroidsFused-Ring CompoundsPolycyclic Compoundsgamma-CyclodextrinsCyclodextrinsMacrocyclic CompoundsDextrinsStarchGlucansPolysaccharidesCarbohydratesCholineTrimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic ChemicalsSuccinatesDicarboxylic AcidsAcids, AcyclicCarboxylic AcidsOnium CompoundsPhenylammonium Compounds

Study Officials

  • Petr Štourač, MD

    Brno Faculty hospital, department of anesthesiology and intensive care medicine

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

October 24, 2012

First Posted

October 31, 2012

Study Start

September 1, 2012

Primary Completion

January 1, 2015

Study Completion

January 1, 2015

Last Updated

July 26, 2016

Record last verified: 2016-07

Locations